Related Experiment Video

Updated: Jan 5, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

8.0K

T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma

Sheng Zhong1,2, Bo Wu2,3, Jiahui Li4

  • 1Department of Neurosurgery, The First Hospital of Jilin University, Changchun, China.

Aging
|October 28, 2019
PubMed

Insights

Three drugs, T5224, RSPO2, and AZD5363, show therapeutic potential against functioning pituitary adenoma (FPA). These agents reduced tumor cell viability and increased apoptosis in vitro, indicating promise for FPA treatment.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Functioning pituitary adenoma (FPA) poses a significant clinical challenge.
  • Identifying novel therapeutic targets for FPA is crucial.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of T5224, RSPO2, and AZD5363 against FPA.
  • To identify potential molecular targets and biomarkers for FPA treatment.

Main Methods:

  • Analysis of FPA gene expression datasets from the Gene Expression Omnibus database.
  • In vitro assays including colony formation, MTT, and flow cytometry.
  • Quantitative reverse transcription polymerase chain reaction (qRT-PCR) for hub gene expression analysis.

Main Results:

  • T5224, RSPO2, and AZD5363 significantly reduced FPA cell viability, proliferation, and clonogenicity in vitro.
  • These drugs induced apoptosis in FPA cells in a dose-dependent manner.
  • Abnormal expression of cFos, WNT5A, NCAM1, JUP, AKT3, and ADCY1 was observed in FPA cells.

Conclusions:

  • T5224, RSPO2, and AZD5363 demonstrate significant therapeutic potential for functioning pituitary adenoma.
  • The identified genes (cFos, WNT5A, NCAM1, JUP, AKT3, ADCY1) represent potential prognostic and therapeutic targets for FPA.
Keywords:
bioinformaticsbrain sciencedrug treatmentfunctional pituitary adenomasprognosis

More Related Videos

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.4K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.1K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
401
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K